Oral cancer pain linked to disease spread

Source: www.docwirenews.com
Author: Robert Dillard

Oral cancer is more likely to spread in patients who experience high levels of pain, according to a study published in the journal Scientific Reports.

When oral cancer spreads to lymph nodes in the neck, a patient’s chance of survival is cut by half, the researchers noted. However, it’s often unclear through imaging and physical assessment if oral cancer has spread, leaving surgeons struggling with whether to preemptively perform prophylactic neck dissection to remove the cancer when research shows that up to 70% are unnecessary.

Researchers documented the pain experienced by 72 oral cancer patients before surgery by way of an oral cancer pain questionnaire developed by the investigators. While most patients reported some pain, researchers observed that patients with the most pain were more likely to have cancer that spread to lymph nodes in the neck. This observation suggests that patients with less pain are at low risk of metastasis, and will rarely benefit from a neck dissection.

“I have been investigating the underlying cause of oral cancer pain for two decades. This is the first time that we have demonstrated a correlation between a patient’s pain and the clinical behavior of the cancer,” said Brian L. Schmidt, DDS, MD, PhD, director of the NYU Oral Cancer Center and one of the study’s authors via a press release.

Aditi Bhattacharya, PhD, an assistant professor in the Department of Oral and Maxillofacial Surgery at NYU College of Dentistry added: “While we need to undertake a follow-up study, our current data reveal that a patient’s pain intensity score works as well as the current method–depth of invasion, or how deeply a tumor has invaded nearby tissue–as an index to predict metastasis.”

Print Friendly, PDF & Email

With 3 new movies on the horizon, Val Kilmer is an inspiration to anyone facing cancer

Source: www.survivornet.com
Author: staff

Val Kilmer, 60, is stepping back into Hollywood in full force. The actor took a hiatus from the red carpet after his battle with throat cancer, but now it’s clear he doesn’t plan to stop again.

Kilmer has been recently cast in upcoming biopic Canyon Del Muerto, following the real-life story of Ann Axtell Morris — one of America’s first female archeologists and leading discoverers of North America’s primary civilizations in Arizona. So far, it’s unclear what character Kilmer will be portraying, but we have no doubt he’ll rise to the occasion. He took a hiatus from acting due to his battle with throat cancer a few years back, but now he’s back and taking on new roles.

In addition to the biopic, Kilmer is preparing for the long anticipated Top Gun sequel, Top Gun: Maverick. The film is set to premiere in July 2021, and Kilmer will be reprising his role as iconic Admiral Tom “Iceman” Kazansky. Additionally, he’ll be starring alongside his daughter Mercedes in Pay Dirt, set to release in October. It’s so nice to see Kilmer return to the big screen, since before his throat cancer diagnosis, he was known as quite the Hollywood heartthrob.

His hiatus from acting is likely due to the side-effects he suffered as a result of his tracheotomy — a surgical procedure that connects the windpipe to a hole in the front of the neck. This is a common part of treatment for throat cancer patients, but as a result of the procedure, Kilmer’s voice has been significantly impaired. Initially, Kilmer kept his battle with throat cancer private, but after a lot of speculation from fans, he eventually shared his journey in 2017.

Print Friendly, PDF & Email

Smell of a person’s breath may help identify early cancers

Source: www.theweek.in
Author: staff

Cancer researchers from Flinders University have reported significant progress in developing a method to test exhaled breath profiles which accurately differentiate head and neck cancer from non-cancer patients.

Previous studies elsewhere have indicated that the exhaled breath condensate can reveal gene mutations or DNA abnormalities in patients with lung cancer.

The global quest to use a person’s breath analysis for rapid, inexpensive and accurate early-stage testing for cancer and other diseases has taken a leap forward.

The Australian researchers collected breath samples from 181 patients suspected of having early-stage head and neck squamous cell carcinoma (HNSCC) before any treatment began.

“We sought to determine the diagnostic accuracy of breath analysis as a non-invasive test for detecting head and neck cancer, which in time may result in a simple method to improve treatment outcomes and patient morbidity,” says lead researchers Dr Roger Yazbek and Associate Professor Eng Ooi.

Worldwide, head and neck cancer accounts for 6 percent of all cancers, killing more than 300,000 people per year globally. Tobacco, alcohol and poor oral hygiene are known major risk factors for this cancer.

A surge in human papilloma virus (HPV)-associated head and neck cancers is seeing these cancers affecting a much younger population, the researchers say.

Current therapies are effective at treating early-stage disease, however late-stage presentations are common, and often associated with poor prognosis and high treatment-related morbidity.

In the Australian study, a selected ion flow-tube mass spectrometer was used to analyse breath for volatile organic compounds. Using statistical modelling, the Flinders researchers were able to develop a breath test that could differentiate cancer and control (benign disease) patients, with an average sensitivity and specificity of 85 percent.

Diagnosis was confirmed by analysis of tissue biopsies.

“With these strong results, we hope to trial the method in primary care settings, such as GP clinics, to further develop its use in early-stage screening for HNSCC in the community,” says co-lead author Dr Nuwan Dharmawardana.

The study has been published in the British Journal of Cancer.

Print Friendly, PDF & Email

Cancer drug for photoimmunotherapy approved: Japan approves drug used in new treatment

Source: www3.nhk.or.jp
Author: press release

A drug for a new cancer treatment called photoimmunotherapy has been granted government approval for the first time. Japan’s government approved the drug last week to treat head and neck cancers, which are difficult to treat with other methods.

US National Institutes of Health researcher Kobayashi Hisataka, who created the method, and Rakuten Medical, which developed the drug, held a news conference in Tokyo on Tuesday.

Photoimmunotherapy involves a combination of a drug that uses antibodies to target cancer cells and chemicals that react to light.

The drug is administered intravenously, and is activated when the patient’s body is illuminated with near-infrared laser light, killing cancer cells.

Kobayashi said he’s overjoyed that the method he’s been engaged in for decades was approved in Japan, and hopes it will be another option for cancer treatment.

Rakuten Medical Chairman Mikitani Hiroshi said he believes the method can be combined with chemotherapy, and hopes to use it to treat patients as soon as possible.

Procedures are to be carried out so that use of the drug is covered by insurance. Since the drug was approved quickly, its safety and effectiveness will continue to be assessed after it goes onto the market.

Print Friendly, PDF & Email
2020-09-30T05:30:04-07:00September, 2020|Oral Cancer News|

A deep learning algorithm for detection of oral cavity squamous cell carcinoma from photographic images: a retrospective study

Source: www.thelancet.com
Authors: Qiuyun Fu et al.


The overall prognosis of oral cancer remains poor because over half of patients are diagnosed at advanced-stages. Previously reported screening and earlier detection methods for oral cancer still largely rely on health workers’ clinical experience and as yet there is no established method. We aimed to develop a rapid, non-invasive, cost-effective, and easy-to-use deep learning approach for identifying oral cavity squamous cell carcinoma (OCSCC) patients using photographic images.

We developed an automated deep learning algorithm using cascaded convolutional neural networks to detect OCSCC from photographic images. We included all biopsy-proven OCSCC photographs and normal controls of 44,409 clinical images collected from 11 hospitals around China between April 12, 2006, and Nov 25, 2019. We trained the algorithm on a randomly selected part of this dataset (development dataset) and used the rest for testing (internal validation dataset). Additionally, we curated an external validation dataset comprising clinical photographs from six representative journals in the field of dentistry and oral surgery. We also compared the performance of the algorithm with that of seven oral cancer specialists on a clinical validation dataset. We used the pathological reports as gold standard for OCSCC identification. We evaluated the algorithm performance on the internal, external, and clinical validation datasets by calculating the area under the receiver operating characteristic curves (AUCs), accuracy, sensitivity, and specificity with two-sided 95% CIs.

1469 intraoral photographic images were used to validate our approach. The deep learning algorithm achieved an AUC of 0·983 (95% CI 0·973–0·991), sensitivity of 94·9% (0·915–0·978), and specificity of 88·7% (0·845–0·926) on the internal validation dataset (n = 401), and an AUC of 0·935 (0·910–0·957), sensitivity of 89·6% (0·847–0·942) and specificity of 80·6% (0·757–0·853) on the external validation dataset (n = 402). For a secondary analysis on the internal validation dataset, the algorithm presented an AUC of 0·995 (0·988–0·999), sensitivity of 97·4% (0·932–1·000) and specificity of 93·5% (0·882–0·979) in detecting early-stage OCSCC. On the clinical validation dataset (n = 666), our algorithm achieved comparable performance to that of the average oral cancer expert in terms of accuracy (92·3% [0·902–0·943] vs 92.4% [0·912–0·936]), sensitivity (91·0% [0·879–0·941] vs 91·7% [0·898–0·934]), and specificity (93·5% [0·909–0·960] vs 93·1% [0·914–0·948]). The algorithm also achieved significantly better performance than that of the average medical student (accuracy of 87·0% [0·855–0·885], sensitivity of 83·1% [0·807–0·854], and specificity of 90·7% [0·889–0·924]) and the average non-medical student (accuracy of 77·2% [0·757–0·787], sensitivity of 76·6% [0·743–0·788], and specificity of 77·9% [0·759–0·797]).

Automated detection of OCSCC by deep-learning-powered algorithm is a rapid, non-invasive, low-cost, and convenient method, which yielded comparable performance to that of human specialists and has the potential to be used as a clinical tool for fast screening, earlier detection, and therapeutic efficacy assessment of the cancer.

Print Friendly, PDF & Email
2020-09-24T13:41:39-07:00September, 2020|Oral Cancer News|

Deadly Spread of Some Cancers May Be Driven by a Common Mouth Microbe

Source: Scientific American
Author: Claudia Wallis
Image courtesy of Fatinha Ramos

When people hear that they might have cancer, perhaps the only thing more frightening than the C word is the M word. Metastatic disease—in which the malignancy has traveled beyond its primary site to other spots in the body—is responsible for nine out of every 10 cancer deaths.

Recently an unexpected player in this process has emerged: a common bacterium. Fusobacterium nucleatum, which normally lives harmlessly in the gums, appears to have a role in the spread of some cancers of the colon, esophagus, pancreas and—possibly—breast. Laboratory studies and evidence in patients indicate that the microbe can travel through the blood and infect tumor cells by attaching to a sugar molecule on their surface. There it provokes a range of signals and immune responses known to cause tumor cells to migrate. If further confirmed, the work with F. nucleatum could add to a growing understanding of how the microbiome influences cancer progression and may even point the way to fresh approaches to treatment.
In a healthy human mouth, F. nucleatum is a law-abiding member of the microbial community. With poor dental hygiene, uncontrolled diabetes and other conditions, however, it can go rogue and cause periodontitis, tonsillitis, appendicitis and even preterm labor. A connection to colorectal cancer was first hinted at about nine years ago, when two research groups discovered that the bacterium’s DNA was overrepresented in colon tumor tissue compared with normal tissue. Dozens of studies have since found that the infection in tumor cells is a sign of trouble: it is linked to a poorer prognosis in patients with pancreatic, esophageal or colorectal cancer; resistance to chemotherapy in the latter two groups; and metastasis in colorectal cancer, which is the world’s third most common and second most deadly malignancy.

Still, the question remained: Is this bug merely a warning sign, or is it an active participant in cancer progression? This year at least three studies of colon cancer, by separate teams, pointed to an active role. “We reached the same conclusion through different pathways,” says biochemist Daniel Slade of Virginia Tech. Slade and his colleagues found that when cultured human colon tumor cells were invaded by the bacterium, they produced two inflammatory proteins called cytokines—specifically, interleukin-8 and CXCL1—that have been shown to promote the migration of malignant cells, a step in metastasis. A second paper reported that the bacterium induces changes in gene regulation that boost metastasis to the lungs in mice. A third study determined that the abundance of F. nucleatum in human colon cancer tissue correlates with the amount of metastases and, in mice, identified additional signals by which the microbe may “orchestrate” metastasis. Slade and others have also demonstrated that the bacterium incites a kind of cytokine storm that is aimed at controlling the infection but that ultimately exacerbates the cancer. “It’s like throwing gas on an already lit fire,” Slade says.

Something similar may be going on in some breast tumors. In June a team led by microbiologist Gilad Bachrach of Hebrew University reported finding F. nucleatum DNA in 30 percent of the human breast cancer tissue examined; the bacterium was most common in cancer cells that expressed a lot of the surface sugar molecule Gal/GalNAc. Researchers also showed that the infection promotes growth of both primary tumors and metastases in mouse models of breast cancer. “The data imply that fusobacterium is not a cause of cancer, but it can accelerate progression,” Bachrach says.

How much this is happening in humans is, of course, a critical question. “The findings are intriguing, and it makes sense,” says Joan Massagué of Memorial Sloan Kettering Cancer Center, who is a leading investigator of metastasis. Inflammation is invariably part of the metastatic process, he says, so an infection that incites a dramatic inflammatory reaction in a tumor will have a consequence: “it helps cancer cells engage in mobile, invasive behavior.”

The discoveries about fusobacterium are part of a fast-moving field that is illuminating the way the microbiome both promotes and battles cancer. Many modern immunotherapy drugs, for instance, work best in the presence of beneficent microbes—as do some older chemotherapies. Some scientists envision that fusobacterium eventually could be turned into a cancer fighter. Given the microbe’s attraction to a sugar on tumor cells, they suggest, perhaps it could be deployed as a Trojan horse, bound to cancer drugs and carrying them straight to a malignant target.

Print Friendly, PDF & Email
2020-09-24T11:24:02-07:00September, 2020|Oral Cancer News|

FDA clears IND application for cell therapy to treat radiotherapy-induced dry mouth

Source: www.healio.com
Author: staff

The FDA cleared an investigational new drug application for a mesenchymal stromal cell therapy to treat radiotherapy-induced xerostomia, also known as dry mouth.

Researchers at University of Wisconsin Carbone Cancer Center developed the therapy, which uses the patient’s interferon-gamma activated marrow stromal cells.

Xerostomia is a one of the most common adverse effects of radiation therapy for head and neck cancers and may cause difficulties eating, speaking and sleeping, in addition to oral health complications.

“There is a critical need for improved treatments for this condition,” Randy Kimple, MD, PhD, associate professor of human oncology at University of Wisconsin School of Medicine, said in a press release. “For most patients, the best care we can provide currently is to encourage them to eat specially prepared food, suck on hard sugar-free candies and carry a water bottle with them all day.”

Kimple told Healio the therapy process involves the patient undergoing a bone marrow biopsy to harvest mesenchymal stromal cells.

Kimple — who will lead the forthcoming phase 1 trial for the therapy — said the cells will be prepared by the Program for Advanced Cell Therapy’s lab at UW Health’s University Hospital. Patients will receive the therapy via injection into the submandibular gland after completion of radiation therapy.

The phase 1 trial soon will begin enrolling up to 30 patients and will be conducted by University of Wisconsin School of Medicine and Public Health as a single-center study of patients treated at Carbone Cancer Center.

Study participants will be monitored for safety and development of adverse effects after receiving the cell therapy injection.

“Patients will also provide samples of their saliva and complete quality-of-life questionnaires to help determine if the treatment is effective,” Kimple said.

Researchers hope to complete the first phase of the trial within a year, according to Kimple.

Print Friendly, PDF & Email
2020-09-12T10:26:52-07:00September, 2020|Oral Cancer News|

Mouth cancer rates set to go ‘through the roof’ following missed dental appointments

Source: www.dentistry.co.uk
Author: staff

Mouth cancer rates are set to skyrocket in the UK following millions of missed dental appointments as a result of lockdown. This is according to the Association of Dental Groups (ADG), which is calling on ministers to take urgent action.

Dentists have warned that thousands of cases may have gone undetected. This could be due to the public avoiding dental practices, as well as the two and a half month pause on face-to-face dental appointments.

For example, 49% of households have at least one adult who has missed or decided against visiting the dentist. Considering there are 27.8 million households across the UK, these figures suggest 13 million adults have missed an appointment.

Calls for urgent action
Part of a major campaign urging ministers to rescue the worsening dentistry crisis in the UK, the ADG poll revealed:

  • 17% of households have someone who missed a visit because they struggled to get an appointment
  • 13% of households have someone who decided against making an appointment
  • 11% of households have someone who decided not to go in for a scheduled check up
  • 12% of households have someone who did not go to the dentist for another reason.

The latest figures show that more than 8,300 people in the UK are diagnosed with mouth cancer every year. Additionally, an estimated 2,700 people lost their life to mouth cancer last year. And over the last year, new cases have increased by 10%.

Deeply alarming
‘The fact that so many people are either failing to get dental appointments, or simply deciding against them, is deeply alarming,’ said ADG chair Neil Carmichael.

‘It suggests that a whole host of oral health problems are being bottled up during lockdown. And that dentists will be overwhelmed when routine appointments restart.

‘Dentists are especially concerned about mouth cancer as routine check-ups are the key to early diagnosis. If this is not happening and the early warning signs are not being detected, then mouth cancer rates could soon go through the roof.

‘Ministers must now take urgent action to ensure that we have the NHS dentists we need to deal with what’s around the corner.’

Print Friendly, PDF & Email
2020-09-11T06:28:46-07:00September, 2020|Oral Cancer News|

Need another reason not to vape? Your oral health is at risk

Source: www.health24.com
Author: Healthday staff

The warnings about vaping – inhaling the vapour of electronic cigarettes – tend to focus on the potential dangers to the heart and lungs. But an increasing amount of research shows the chemicals in e-cigarettes start to inflict damage right where they enter the body: your mouth.

Because e-cigarettes are a recent phenomenon, said Dr Crystal Stinson, assistant professor at Texas A&M College of Dentistry in Dallas, “Studies on their impact are really new. But now we have a solid amount of evidence that shows the link between e-cigarettes and poor oral health.”

Nicotine, whether smoked or vaped, restricts blood flow to the gums, which can contribute to periodontal disease. The fluid in e-cigarettes, which can include propylene glycol, benzene, formaldehyde and other chemicals, only increases the risks.

Irreversible issues
A study published earlier this year in the journal iScience showed that 43% of people using e-cigarettes had gum disease and oral infections. That figure was higher among smokers – 73% – but only 28% among people who neither smoked nor vaped.

“The oral cavity is really resilient tissue that heals faster than other parts of the body,” Stinson said. “But we also know that when you repeatedly traumatise it, that’s when you end up having issues that are irreversible.”

Those issues, she added, range from inflammation and tooth cavities to loss of bone that anchors teeth to the jaw, called periodontitis, and oral cancer.

Another study published in May in Science Advances concluded the oral microbiome – the vast collection of friendly bacteria, viruses and other microbes that live in the mouth – of e-cigarette users without gum disease looked a lot like the microbiome of people with periodontitis.

“It’s absolutely scary stuff,” said Dr Purnima Kumar, professor at the Ohio State University College of Dentistry and the study’s senior author. “E-cigarettes stress the bacterial communities that live in your mouth, and they encase themselves in slime. So they’re no longer good bacteria and the inflammatory response is through the roof. People are walking around thinking they’re healthy, but they are just primed for disease.”

‘We’ve just scratched the surface’
Oral health is a critical element of whole-body health. Two preliminary studies presented in February at the American Stroke Association’s International Stroke Conference linked gum disease with a higher rate of strokes caused by hardening of large arteries in the brain and also with severe artery blockages. A 2018 study in the American Heart Association journal Hypertension found that gum disease appears to worsen high blood pressure and interferes with medications to treat hypertension.

Last December, the American Dental Association issued a statement urging a ban on e-cigarettes not approved by the Food and Drug Administration to help people quit smoking, as well as more research on the effects of vaping on oral health.

“We’ve just scratched the surface,” Kumar said. “We know it’s detrimental. We need to start looking at which chemical components of vape really cause this, why does it cause this, how long does it take to start, and how long does the body need to recover once you quit.”

Not enough time has passed since vaping became popular to assess the long-term dangers, Stinson said. “Unfortunately, everybody’s an experiment right now.”

But Stinson doesn’t need to wait for more studies to be convinced of the dangers of vaping. One look inside a vaper’s mouth usually tells the story.

More cavities
“Periodontal disease is normally an adult disease, and we’re seeing it in younger people,” she said. “Younger people normally have more saliva than they need, so when they present with dry mouth, periodontal disease or increased complaints of mouth ulcers, our next question is, ‘Do you vape?’ These symptoms are all tied to components in e-cigarettes.”

She also notices more cavities in her younger patients who vape, which she believes may be due to the acidity of the components in vape liquid and an increase in cavity-causing bacteria.

Stinson attributes the high rate of nicotine dependence to the sweet flavourings that helped attract adolescents to e-cigarettes. In February, the FDA banned many flavoured e-cigarettes in hopes of reducing the rise in vaping among young people, but health experts fear many are already hooked on nicotine.

“Phasing out the flavours is going to help, but we still have a population that is struggling to let go of the habit,” she said.

Both Stinson and Kumar are involved in education and cessation programmes aimed at convincing young people not to start vaping and helping those who do to stop.

‘It’s not a vapour’
The first lesson: Don’t be fooled into thinking that what looks like steam is a safe alternative to cigarette smoke.

“You hear ‘vapour’ and you think steam facials or a tea kettle,” Kumar said. “It’s not a vapour. It’s an aerosol, like hairspray or what you use to kill ants and cockroaches. When I teach young kids, I take little cans of hairspray and say, ‘I want you to spray this in your mouth.’

“They say, ‘Ew, no.’ So, I say, ‘Then why would you vape?'”

Print Friendly, PDF & Email
2020-09-08T06:09:52-07:00September, 2020|Oral Cancer News|

Scientists have combined two potent immunotherapies to eliminate big tumors

Source: www.drewreportsnews.com
Author: Drew Simms

City of Hope researchers have actually combined two potent immunotherapies– an oncolytic infection and chimeric antigen receptor (CAR) T cell therapy– to target and remove solid growths that are otherwise difficult to treat with CAR T treatment alone, according to a brand-new Science Translational Medication study.

In pre-clinical research that could lead to a medical trial for clients with intractable solid tumors, City of Hope scientists genetically crafted an oncolytic virus to go into growth cells and require their expression of CD19 protein on their cell surface area. Scientists were then able to use CD19-directed CAR T cells to recognize and attack these solid tumors.

CD19-CAR T cell therapy is authorized by the U.S. Fda to treat particular types of blood cancers, specifically B cell lymphomas and intense lymphoblastic leukemia. This brand-new research might broaden using CD19-CAR T cells for the treatment of patients with possibly any strong tumor.

“Our research demonstrates that oncolytic viruses are a powerful and promising approach that can be combined strategically with CAR T cell therapy to more effectively target solid tumors” said Saul Priceman, Ph.D., the study’s senior author and an assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation.

“In addition, this therapeutic platform addresses two major challenges that make solid tumors so difficult to treat with immunotherapy. There are limited, established solid tumor targets that T cells can be redirected against with CARs,” Priceman added. “Furthermore, solid tumors are surrounded by a brick wall — a so-called immunosuppressive tumor microenvironment. When a CAR T cell attempts to enter the tumor, survive, and kill cancer cells, it can’t effectively because of this barrier.”

Yuman Fong, M.D., the Sangiacomo Family Chair in Surgical Oncology at City of Hope and a leading researcher who is developing oncolytic infections for cancer treatment, included that the virus had the ability to break through that barrier.

“We designed this oncolytic virus to do what it does so well,” Fong said. “It entered the cancer cell and used the cell’s own machinery to replicate itself, and engineer the cancer cells to express a truncated form of the well-known CAR T cell target, CD19.”

Researchers first produced an oncolytic infection (OV19t) in Fong’s lab to enter into tumor cells and start producing truncated CD19 (CD19t). They did this successfully in triple-negative breast cancer lines, along with in pancreatic, prostate, ovarian, and head and neck cancer, as well as brain growth cells. CD19-CAR T cells were then integrated with OV19t in vitro and in healing studies in mice.

Scientists found several crucial findings
“When we infected tumor cells with the virus, we observed the first signal that this may work. CD19t was being expressed by tumor cells much sooner than the virus was able to kill them, giving us a window of opportunity to be targeted by CD19-CAR T cells,” said Anthony Park, Ph.D., a postdoctoral fellow in Priceman’s lab. “The combination of the two had a powerful, synergistic effect.”

Researchers also revealed that mice already treated of their cancer with the oncolytic infection and CAR T cell combination showed extended protective anti-tumor resistance.

“The immune system built a memory response to the tumor,” Park added. “Once it eradicated tumors, following the initial combination treatment, the mice were shielded against tumor recurrences.”

Solid growths are frequently immunologically cold, which implies they are not usually responsive to therapies that utilize the body’s own immune system to eliminate cancer, Park said. Introducing the virus reversed the tumor’s harsh microenvironment, making it more receptive to receiving CAR T cell treatment.

The research study shows City of Hope’s collective technique to finding much better immunotherapy cancer treatments. A couple of years back, Priceman, Fong and Stephen Forman, M.D., leader of City of Hope’s Hematologic Malignancies Research Institute, satisfied to conceptualize how they might integrate their know-how, namely oncolytic infection and CAR T cell treatments, to target solid growths.

“It was a simple concept but one that took many steps to get us to where we are today — we are now designing a clinical trial to test this combination in patients,” said Priceman.

The trial would initially check the safety of OV19t in clients with solid growths. If that is found to be safe and effective, the oncolytic virus and CAR T cell treatment could then be checked in sequence. The trial is anticipated to begin in 2022.

City of Hope, an acknowledged leader in CAR T cell treatments for blood cancers and strong growths, has actually dealt with more than 500 clients because its CAR T program begun in the late 1990s. The organization continues to have among the most comprehensive CAR T cell clinical research study programs on the planet. It currently has 30 ongoing CAR T scientific trials, consisting of CAR T trials for blood cancers and several strong growth types such as primary and metastatic brain growths, metastatic castration resistant prostate cancer, and more.

Print Friendly, PDF & Email
2020-09-07T10:52:20-07:00September, 2020|Oral Cancer News|
Go to Top